Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

RECURSION PHARMACEUTICALS, INC. (RXRX)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19
   8-K10-K10-K10-K
Revenues  39.810.24.02.3
            Revenue growth  291.5%156.9%70.8% 
Cost of goods sold  48.30.00.00.0
Gross profit  -8.410.24.02.3
            Gross margin  -21.2%100.0%100.0%100.0%
Selling, general and administrative   [+]81.657.725.319.0
Research and development  155.7135.363.345.8
EBITDA   [+] -174.4-80.7-60.0
            EBITDA margin  -616.7%-1713.2%-2036.1%-2585.3%
Depreciation   8.13.82.5
EBITA  -245.7-182.5-84.5-62.4
            EBITA margin  -616.7%-1792.8%-2132.5%-2692.6%
Amortization of intangibles   0.30.1 
EBIT   [+]-245.7-182.8-84.6-62.4
            EBIT margin  -616.7%-1795.8%-2135.7%-2692.6%
Interest expense, net   [+] -0.1-0.3-1.7
Other income (expense), net  6.3-0.8-1.4-0.5
Pre-tax income  -239.5-186.5-87.0-61.9
Income taxes  0.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%
Net income  -239.5-186.5-87.0-61.9
            Net margin  -601.0%-1832.2%-2196.0%-2668.3%
   
Basic EPS   [+] ($1.49)($3.99)($2.87)
Diluted EPS   [+] ($1.49)($3.99)($2.87)
   
Shares outstanding (basic)   [+] 125.321.821.6
Shares outstanding (diluted)   [+] 125.321.821.6
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy